{"id":"gw685698","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X7 receptor antagonism reduces the release of pro-inflammatory cytokines such as IL-1β and TNF-α by blocking ATP-mediated activation of immune cells. This mechanism is intended to suppress excessive inflammatory responses in conditions characterized by P2X7-driven pathology, particularly in inflammatory and autoimmune diseases.","oneSentence":"GW685698 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:43.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT05757102","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-04-25","conditions":"Asthma","enrollment":292},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":"Asthma","enrollment":906},{"nctId":"NCT03184480","phase":"","title":"Arnuity® Ellipta® Drug Use Investigation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-19","conditions":"Asthma","enrollment":336},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT01706198","phase":"PHASE3","title":"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-01","conditions":"Asthma","enrollment":4233},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT00358475","phase":"PHASE3","title":"Study Of Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-21","conditions":"Rhinitis, Allergic, Seasonal","enrollment":65},{"nctId":"NCT00363740","phase":"PHASE3","title":"Study of GW685698X In Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02-19","conditions":"Rhinitis, Allergic, Seasonal","enrollment":38},{"nctId":"NCT01395888","phase":"PHASE3","title":"A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":260},{"nctId":"NCT02164539","phase":"PHASE2","title":"Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":338},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT01266941","phase":"PHASE1","title":"A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-18","conditions":"Asthma","enrollment":35},{"nctId":"NCT01299558","phase":"PHASE1","title":"Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":"Asthma","enrollment":16},{"nctId":"NCT01209026","phase":"PHASE1","title":"Corrected QT (QTc) Study With Flucticasone Furoate and GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-23","conditions":"Asthma","enrollment":85},{"nctId":"NCT01551758","phase":"PHASE3","title":"A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2802},{"nctId":"NCT02064504","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT01894386","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT00730756","phase":"PHASE2","title":"A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Rhinitis, Allergic, Perennial","enrollment":102},{"nctId":"NCT01332292","phase":"PHASE2","title":"Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Asthma","enrollment":27},{"nctId":"NCT01498679","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":311},{"nctId":"NCT01498653","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT00731822","phase":"PHASE2","title":"A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":4,"reaction":"PNEUMONIA"},{"count":2,"reaction":"DYSPHONIA"},{"count":2,"reaction":"OESOPHAGEAL CANDIDIASIS"},{"count":1,"reaction":"ANAPHYLACTOID REACTION"},{"count":1,"reaction":"ANGINA UNSTABLE"},{"count":1,"reaction":"AORTIC ANEURYSM"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"ATRIAL FLUTTER"},{"count":1,"reaction":"BLADDER NEOPLASM"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GW685698","genericName":"GW685698","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GW685698 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Rheumatoid arthritis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}